University of South Florida, Tampa, FL, USA.
Expert Rev Neurother. 2013 Dec;13(12):1329-42. doi: 10.1586/14737175.2013.859986.
Parkinson's disease (PD) is a progressive neurodegenerative disease, involving the dopaminergic, noradrenergic, serotonergic and cholinergic systems. In addition to its cardinal motor symptoms, PD is associated with a diverse range of non-motor symptoms (NMS) that may be more important than motor symptoms. Although there is evidence for a dopaminergic contribution for several NMS in PD, NMS have been underrecognized and undertreated by clinicians. There is evidence that dopaminergic therapy, including dopamine agonists, may alleviate some NMS, such as anxiety and depression. This review focuses on published data on the effects of the non-ergoline dopaminergic agonist rotigotine transdermal system in the treatment of NMS in patients with PD. Data on the effects of orally administered non-ergoline agonists, including ropinirole and pramipexole, on NMS are also summarized.
帕金森病（PD）是一种进行性神经退行性疾病，涉及多巴胺能、去甲肾上腺素能、5-羟色胺能和胆碱能系统。除了主要的运动症状外，PD 还与多种非运动症状（NMS）相关，这些症状可能比运动症状更为重要。尽管有证据表明多巴胺能对 PD 的几种 NMS 有贡献，但临床医生对 NMS 的认识不足，治疗不足。有证据表明，多巴胺能治疗，包括多巴胺激动剂，可能缓解一些 NMS，如焦虑和抑郁。本综述重点介绍了已发表的关于非麦角碱多巴胺激动剂罗替高汀透皮系统治疗 PD 患者 NMS 的疗效数据。还总结了口服非麦角碱激动剂（包括罗匹尼罗和普拉克索）对 NMS 的疗效数据。
